Cargando…
Nucleosides and emerging viruses: A new story
With several US Food and Drug Administration (FDA)-approved drugs and high barriers to resistance, nucleoside and nucleotide analogs remain the cornerstone of antiviral therapies for not only herpesviruses, but also HIV and hepatitis viruses (B and C); however, with the exception of severe acute res...
Autores principales: | Roy, Vincent, Agrofoglio, Luigi A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856764/ https://www.ncbi.nlm.nih.gov/pubmed/35189369 http://dx.doi.org/10.1016/j.drudis.2022.02.013 |
Ejemplares similares
-
Drug combination therapy for emerging viral diseases
por: Shyr, Zeenat A., et al.
Publicado: (2021) -
How to build a tumor: An industry perspective
por: Schueler, Julia, et al.
Publicado: (2022) -
Repurposing drugs as COVID-19 therapies: A toxicity evaluation
por: Ngan, Deborah K., et al.
Publicado: (2022) -
The current status of COVID-19 vaccines. A scoping review
por: Rueda-Fernández, Manuel, et al.
Publicado: (2022) -
Myotonic dystrophy type 1 drug development: A pipeline toward the market
por: Pascual-Gilabert, Marta, et al.
Publicado: (2021)